Skip to main content

Palmoplantar Pustulosis

2
Pipeline Programs
5
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 2 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Eppendorf
EppendorfGermany - Hamburg
1 program
1
ApremilastPhase 21 trial
Active Trials
NCT04572997Completed21Est. Aug 2019
Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
Delgocitinib creamPhase 21 trial
Active Trials
NCT07013201Recruiting135Est. Dec 2026
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
1 program
ImsidolimabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT03633396Completed59Est. Apr 2021
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
SpesolimabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT04493424Terminated108Est. May 2023
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
BimekizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT07219420Recruiting300Est. Nov 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UCB PharmaBimekizumab
Leo PharmaDelgocitinib cream
Boehringer IngelheimSpesolimab
Vanda PharmaceuticalsImsidolimab
EppendorfApremilast

Clinical Trials (5)

Total enrollment: 623 patients across 5 trials

NCT07219420UCB PharmaBimekizumab

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Start: Nov 2025Est. completion: Nov 2029300 patients
Phase 3Recruiting
NCT07013201Leo PharmaDelgocitinib cream

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Start: Sep 2025Est. completion: Dec 2026135 patients
Phase 2Recruiting
NCT04493424Boehringer IngelheimSpesolimab

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Start: Sep 2020Est. completion: May 2023108 patients
Phase 2Terminated
NCT03633396Vanda PharmaceuticalsImsidolimab

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Start: May 2019Est. completion: Apr 202159 patients
Phase 2Completed
NCT04572997EppendorfApremilast

Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)

Start: Nov 2018Est. completion: Aug 201921 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 623 patients
Monoclonal Antibody is the dominant modality (100% of programs)
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.